$1.26
8.62% today
Nasdaq, Aug 12, 09:13 pm CET
ISIN
US44148G1058
Symbol
HOTH

Hoth Therapeutics, Inc. Stock price

$1.16
-0.28 19.44% 1M
+0.14 13.73% 6M
+0.41 55.06% YTD
+0.54 85.90% 1Y
-10.20 89.78% 3Y
-72.34 98.42% 5Y
-212.09 99.46% 10Y
-212.09 99.46% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.03 2.52%
ISIN
US44148G1058
Symbol
HOTH
Industry

Key metrics

Basic
Market capitalization
$15.3m
Enterprise Value
$4.0m
Net debt
positive
Cash
$11.3m
Shares outstanding
13.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.3
Financial Health
Equity Ratio
89.2%
Return on Equity
-119.0%
ROCE
-83.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-9.6m | -
EBIT
$-9.6m | $-11.7m
Net Income
$-9.6m | $-10.0m
Free Cash Flow
$-8.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-27.6% | -42.2%
Net Income
-24.9% | -22.2%
Free Cash Flow
-2.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.8
FCF per Share
$-0.6
Short interest
3.1%
Employees
3
Rev per Employee
$0.0
Show more

Is Hoth Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Hoth Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Hoth Therapeutics, Inc. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Hoth Therapeutics, Inc. forecast:

Buy
88%
Hold
13%

Financial data from Hoth Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.90 4.90
1% 1%
-
- Research and Development Expense 4.74 4.74
45% 45%
-
-9.63 -9.63
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -9.64 -9.64
28% 28%
-
Net Profit -9.62 -9.62
25% 25%
-

In millions USD.

Don't miss a Thing! We will send you all news about Hoth Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hoth Therapeutics, Inc. Stock News

Neutral
PRNewsWire
14 days ago
The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK , July 29, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, today announced its engagement with ICON Clinical Research Limited ("ICON") to expand it's Phase II Clinical Trial for cancer patients suffering fro...
Neutral
PRNewsWire
21 days ago
NEW YORK , July 22, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, today announced a CRADA (Cooperative Research and Development Agreement) with the U.S. Department of Veterans Affairs and Foundation for Atlanta Veterans Education and Research (FAVER) to evaluate GDNF (glial cell-derived neurotrophic factor) as a novel metabolic therapy target...
Neutral
PRNewsWire
about 2 months ago
*Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Market Exclusive License from U.S. Department of Veterans Affairs to Advance GDNF-Based Therapy for Obesity and Fatty Liver Disease NEW YORK , June 25, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) and Silo Pharma, Inc. (NASDAQ: SILO) today announced the format...
More Hoth Therapeutics, Inc. News

Company Profile

Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.

Head office United States
CEO Robbie Knie
Employees 3
Founded 2017
Website hoththerapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today